Last reviewed · How we verify
CIS-DPI
At a glance
| Generic name | CIS-DPI |
|---|---|
| Also known as | Cisplatin-based Dry Powder for Inhalation |
| Sponsor | Inhatarget Therapeutics |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Oral candidiasis
- Oesophageal candidiasis
- Dysphonia
- Oral fungal infection
- Upper respiratory tract infection
- Oropharyngeal pain
- Nausea
- Arthralgia
- Myalgia
- Fatigue
- Dizziness
- Dysgeusia
Key clinical trials
- Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung Cancer (PHASE1, PHASE2)
- A Clinical Study to Evaluate the Effect of the Connected Inhaler System (CIS) on Adherence to Maintenance Therapy in Poorly Controlled Asthmatic Subjects (PHASE4)
- Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled Asthma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CIS-DPI CI brief — competitive landscape report
- CIS-DPI updates RSS · CI watch RSS
- Inhatarget Therapeutics portfolio CI